Video

Holli Dilks on Molecular Profiling

Holli Dilks, PhD, Director, Personalized Medicine Operations Sarah Cannon Research Institute, discusses molecular profiling.

Holli Dilks, PhD, Director, Personalized Medicine Operations Sarah Cannon Research Institute, discusses molecular profiling.

Clinical trial eligibility is often dependent on molecular status, but determining which patients should undergo molecular profiling and when can be challenging, said Dilks.

The National Comprehensive Cancer Network (NCCN) offers guideline that can help oncologists determine at which stage of disease patients should be profiled.

Reaching out to pharmaceutical partners to find out the eligibility criteria for patients to enroll can also help oncologists determine when molecular profiling is necessary.

Related Videos
Paolo Tarantino, MD
Aditya Bardia, MD, MPH, FASCO
Giuseppe Curigliano, MD, PhD, director, Early Drug Development Division, co-chair, Experimental Therapeutics Program, the European Institute of Oncology
Mina Lobbous, MD, MPH
Thomas Marron, MD, PhD
Noa Biran, MD
Andrew Hantel, MD
Peter Forsyth, MD
Jakub Svoboda, MD
Joaquim Bellmunt, MD, PhD